Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
In the last 90 days, Vir Biotechnology, Inc. insiders filed 0 open-market purchases and 1 sale; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:20 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $438.0M (638.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 26, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B | $1.10B |
| Cost of revenue | $26.0K | $845.0K | $2.77M | $146.3M | $65.9M |
| Research and development | $456.0M | $506.5M | $589.7M | $474.6M | $448.0M |
| Selling, general and administrative | $92.1M | $119.0M | $178.0M | $161.8M | $160.8M |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M |
| Income tax | $217.0K | -$1.15M | -$13.1M | $238.4M | $21.2M |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M |
| EPS, basic | $-3.16 | $-3.83 | $-4.59 | $3.89 | $4.07 |
| EPS, diluted | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 |
| Weighted shares, basic | 138.5M | 136.2M | 134.1M | 132.6M | 129.9M |
| Weighted shares, diluted | 138.5M | 136.2M | 134.1M | 134.8M | 133.4M |
| Margins and growth | |||||
| Operating margin | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% |
| Net margin | -638.9% | -703.4% | -713.8% | 31.9% | 48.3% |
| Revenue growth, year over year | −7.6% | −13.9% | −94.7% | +47.5% | +1,334.4% |
| Net income growth, year over year | – | – | −219.2% | −2.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 26, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Cash and equivalents | $232.2M | $222.9M | $241.6M | $848.6M | $347.8M |
| Short-term investments | $228.8M | $678.1M | $1.27B | $1.52B | $217.2M |
| Accounts receivable | – | – | – | $0 | $773.1M |
| Total current assets | $514.1M | $1.04B | $1.59B | $2.52B | $1.56B |
| Property, plant and equipment | $55.6M | $63.2M | $96.0M | $105.6M | $42.8M |
| Goodwill | $16.9M | $16.9M | $16.9M | $16.9M | $16.9M |
| Intangible assets | $7.85M | $8.12M | $22.6M | $32.8M | $33.3M |
| Total assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B |
| Accounts payable | $9.80M | $5.08M | $6.33M | $6.42M | $6.52M |
| Total current liabilities | $92.8M | $119.7M | $175.4M | $511.0M | $341.2M |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M |
| Shareholders' equity | $765.3M | $1.15B | $1.59B | $2.08B | $1.43B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 26, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating cash flow | -$391.8M | -$446.4M | -$778.8M | $1.66B | -$47.6M |
| Capital expenditures | $4.83M | $7.30M | $21.6M | $68.0M | $21.8M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.60B | -$69.4M |
| Depreciation and amortization | $11.7M | $14.6M | $18.9M | $6.25M | $5.28M |
| Stock-based compensation | $49.1M | $78.5M | $111.3M | $102.1M | $83.8M |
| Investing cash flow | $310.4M | $499.4M | $164.6M | -$1.19B | -$140.8M |
| Financing cash flow | $3.79M | $4.39M | $7.48M | $34.8M | $100.3M |
| Net change in cash | -$77.6M | $57.4M | -$606.7M | $504.6M | -$88.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 71.6% | 105.7% | 129.2% | 6.3% | 7.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 28, 2026 | 171.3M | +23.1% | SEC |
| Jul 29, 2026 | 169.2M | +21.8% | SEC |
| Apr 29, 2026 | 168.7M | +22.0% | SEC |
| Feb 17, 2026 | 139.5M | +1.7% | SEC |
| Oct 29, 2025 | 139.1M | +1.0% | SEC |
| Jul 30, 2025 | 138.9M | +1.7% | SEC |
| Apr 30, 2025 | 138.2M | +1.6% | SEC |
| Feb 20, 2025 | 137.1M | +1.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.